Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors.

François DozFranco LocatelliAndré BaruchelNicolas BlinBarbara De MoerlooseDidier FrappazMichael DworzakMatthias FischerJan StaryRene FuertigKathrin RiemannTillmann TaubeDirk Reinhardt

Published in: Pediatric blood & cancer (2019)

The pediatric MTD/dose for further development was identified. There were no unexpected safety or PK findings; limited antitumor/antileukemic activity was demonstrated.

Keyphrases

open label
clinical trial
young adults
childhood cancer